NCT03207529: Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer

NCT03207529
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: AR+, ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must also be PTEN+
Exclusions: Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03207529

Comments are closed.

Up ↑